Recent News

• 02.03.2026 - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
• 02.02.2026 - EFFECT - Notice of Effectiveness
• 01.30.2026 - 424B3 - Prospectus [Rule 424(b)(3)]
• 01.21.2026 - S-1 - General form for registration of securities under the Securities Act of 1933
• 01.15.2026 - GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
• 01.08.2026 - 424B3 - Prospectus [Rule 424(b)(3)]
• 12.03.2025 - EFFECT - Notice of Effectiveness
• 12.02.2025 - 424B3 - Prospectus [Rule 424(b)(3)]
• 11.26.2025 - 8-K - Current report
• 11.14.2025 - 10-Q - Quarterly report [Sections 13 or 15(d)]

Recent Filings

• 01.30.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.30.2026 - EFFECT Notice of Effectiveness
• 01.21.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 01.08.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.02.2025 - EFFECT Notice of Effectiveness
• 12.02.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.26.2025 - 8-K Current report
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]